The E3 ubiquitin ligase Itch inhibits p38α signaling and skin inflammation through the ubiquitylation of Tab1

Science Signaling

Volumn 8, Issue 365, 2015, Pages

  Theivanthiran, Balamayooran ^a   Kathania, Mahesh ^a   Zeng, Minghui ^a   Anguiano, Esperanza ^a   Basrur, Venkatesha ^b   Vandergriff, Travis ^c   Pascual, Virginia ^a   Wei, Wei Zen ^d   Massoumi, Ramin ^e   Venuprasad, K ^a  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; E3 UBIQUITIN LIGASE ITCH; INTERLEUKIN 11; INTERLEUKIN 19; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIGASE; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN; SHORT HAIRPIN RNA; TAB1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ITCH PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TAB1 PROTEIN, MOUSE; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DERMATITIS; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MOUSE; MUTANT; NONHUMAN; PRIORITY JOURNAL; PRURITUS; REGULATORY MECHANISM; SKIN; SKIN DEFECT; UBIQUITINATION; WILD TYPE; ANIMAL; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

MUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CYTOKINES; DERMATITIS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, KNOCKOUT; MITOGEN-ACTIVATED PROTEIN KINASE 14; PHOSPHORYLATION; SKIN; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84923645267     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2005903     Document Type: Article

References (63)

1. S. I. Grivennikov, F. R. Greten, M. Karin, Immunity, inflammation, and cancer. Cell 140, 883-899 (2010).
2. V. G. Bhoj, Z. J. Chen, Ubiquitylation in innate and adaptive immunity. Nature 458, 430-437 (2009).
3. C. M. Pickart, Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 70, 503-533 (2001).
4. G. Melino, E. Gallagher, R. I. Aqeilan, R. Knight, A. Peschiaroli, M. Rossi, F. Scialpi, M. Malatesta, L. Zocchi, G. Browne, A. Ciechanover, F. Bernassola, Itch: A HECT type E3 ligase regulating immunity, skin and cancer. Cell Death Differ. 15, 1103-1112 (2008).
5. A. Hershko, A. Ciechanover, The ubiquitin system. Annu. Rev. Bio chem. 67, 425-479 (1998).
6. W. L. Perry, C. M. Hustad, D. A. Swing, T. N. O'Sullivan, N. A. Jenkins, N. G. Copeland, The itchy locus encodes a novel ubiquitin protein ligase that is disrupted in a18H mice. Nat. Genet. 18, 143-146 (1998).
7. J. D. Ashwell, The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat. Rev. Immunol. 6, 532-540 (2006).
8. B. Ge, H. Gram, F. Di Padova, B. Huang, L. New, R. J. Ulevitch, Y. Luo, J. Han, MAPK Kin dependent activation of p38a mediated by TAB1-dependent autophosphorylation of p38a. Science 295, 1291-1294 (2002).
9. G. F. De Nicola, E. D. Martin, A. Chaikuad, R. Bassi, J. Clark, L. Martino, S. Verma, P. Sicard, R. Tata, R. A. Atkinson, S. Knapp, M. R. Conte, M. S. Marber, Mechanism and consequence of the autoactivation of p38a mitogen-activated protein kinase promoted by TAB1. Nat. Struct. Mol. Biol. 20, 1182-1190 (2013).
10. Y. Takanami-Ohnishi, S. Amano, S. Kimura, S. Asada, A. Utani, M. Maruyama, H. Osada, H. Tsunoda, Y. Irukayama-Tomobe, K. Goto, M. Karin, T. Sudo, Y. Kasuya, Essential role of p38 mitogen-activated protein kinase in contact hypersensitivity. J. Biol. Chem. 277, 37896-37903 (2002).
11. J. Hildesheim, R. T. Awwad, A. J. Fornace Jr., p38 mitogen-activated protein kinase inhibitor protects the epidermis against the acute damaging effects of ultraviolet irradiation by blocking apoptosis and inflammatory responses. J. Invest. Dermatol. 122, 497-502 (2004).
12. C. Johansen, K. Kragballe, M. Westergaard, J. Henningsen, K. Kristiansen, L. Iversen, The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. Br. J. Dermatol. 152, 37-42 (2005).
13. A. T. Funding, C. Johansen, M. Gaestel, B. M. Bibby, L. L. Lilleholt, K. Kragballe, L. Iversen, Reduced oxazolone-induced skin inflammation in MAPKAP kinase 2 knockout mice. J. Invest. Dermatol. 129, 891-898 (2009).
14. C. Kim, Y. Sano, K. Todorova, B. A. Carlson, L. Arpa, A. Celada, T. Lawrence, K. Otsu, J. L. Brissette, J. S. Arthur, J. M. Park, The kinase p38a serves cell type-specific inflammatory functions in skin injury and coordinates pro- And anti-inflammatory gene expression. Nat. Immunol. 9, 1019-1027 (2008).
15. M. C. Genovese, Inhibition of p38: Has the fat lady sung? Arthritis Rheum. 60, 317-320 (2009).
16. D. Hammaker, G. S. Firestein, "Go upstream, young man": Lessons learned from the p38 saga. Ann. Rheum. Dis. 69 (Suppl. 1), i77-i82 (2010).
17. N. Weigelt, D. Metze, S. Ständer, Prurigo nodularis: Systematic analysis of 58 histological criteria in 136 patients. J. Cutan. Pathol. 37, 578-586 (2010).
18. D. J. Marble, K. B. Gordon, B. J. Nickoloff, Targeting TNFa rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J. Dermatol. Sci. 48, 87-101 (2007).
19. A. Stratis, M. Pasparakis, R. A. Rupec, D. Markur, K. Hartmann, K. Scharffetter-Kochanek, T. Peters, N. van Rooijen, T. Krieg, I. Haase, Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J. Clin. Invest. 116, 2094-2104 (2006).
20. R. A. Clark, T. S. Kupper, Misbehaving macrophages in the pathogenesis of psoriasis. J. Clin. Invest. 116, 2084-2087 (2006).
21. H. Wang, T. Peters, D. Kess, A. Sindrilaru, T. Oreshkova, N. Van Rooijen, A. Stratis, A. C. Renkl, C. Sunderkötter, M. Wlaschek, I. Haase, K. Scharffetter-Kochanek, Activated macrophages are essential in a murine model for T cell-mediated chronic psoriaI form skin inflammation. J. Clin. Invest. 116, 2105-2114 (2006).
22. N. Ahmed, M. Zeng, I. Sinha, L. Polin, W. Z. Wei, C. Rathinam, R. Flavell, R. Massoumi, K. Venuprasad, The E3 ligase Itch and deubiquitinase Cyld act together to regulate Tak1 and inflammation. Nat. Immunol. 12, 1176-1183 (2011).
23. D. J. Peng, M. Zeng, R. Muromoto, T.Matsuda, K. Shimoda, M. Subramaniam, T. C. Spelsberg, W. Z. Wei, K. Venuprasad, Noncanonical K27-linked polyubiquitination of TIEG1 regulates Foxp3 expression and tumor growth. J. Immunol. 186, 5638-5647 (2011).
24. I. M. Meijer, W. van Rotterdam, E. J. van Zoelen, J. E. van Leeuwen, Cbl and Itch binding sites in ERBB4 CYT-1 and CYT-2 mediate K48- And K63-polyubiquitination, respectively. Cell. Signal. 25, 470-478 (2013).
25. M. Tao, P. C. Scacheri, J. M. Marinis, E. W. Harhaj, L. E. Matesic, D. W. Abbott, ITCH K63-ubiquitinates the NOD2 binding protein, RIP2, to influence inflammatory signaling pathways. Curr. Biol. 19, 1255-1263 (2009).
26. H. Huang, M. S. Jeon, L. Liao, C. Yang, C. Elly, J. R. Yates III, Y. C. Liu, K33-linked polyubiquitination of T cell receptor-z regulates proteolysis-independent T cell signaling. Immunity 33, 60-70 (2010).
27. P. Chastagner, A. Israël, C. Brou, Itch/AIP4 mediates Deltex degradation through the formation of K29-linked polyubiquitin chains. EMBO Rep. 7, 1147-1153 (2006).
28. K. Newton, M. L. Matsumoto, I. E. Wertz, D. S. Kirkpatrick, J. R. Lill, J. Tan, D. Dugger, N. Gordon, S. S. Sidhu, F. A. Fellouse, L. Komuves, D. M. French, R. E. Ferrando, C. Lam, D. Compaan, C. Yu, I. Bosanac, S. G. Hymowitz, R. F. Kelley, V. M. Dixit, Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell 134, 668-678 (2008).
29. H. Shibuya, K. Yamaguchi, K. Shirakabe, A. Tonegawa, Y. Gotoh, N. Ueno, K. Irie, E. Nishida, K. Matsumoto, TAB1: An activator of the TAK1 MAPKKK in TGF-b signal transduction. Science 272, 1179-1182 (1996).
30. H. Zhou, M. Zheng, J. Chen, C. Xie, A. R. Kolatkar, T. Zarubin, Z. Ye, R. Akella, S. Lin, E. J. Goldsmith, J. Han, Determinants that control the specific interactions between TAB1 and p38a. Mol. Cell. Biol. 26, 3824-3834 (2006).
31. G. Lu, Y. J. Kang, J. Han, H. R. Herschman, E. Stefani, Y. Wang, TAB-1 modulates intracellular localization of p38 MAP kinase and downstream signaling. J. Biol. Chem. 281, 6087-6095 (2006).
32. N. Makeeva, G. M. Roomans, J. W. Myers, N. Welsh, Transforming growth factor-bactivated protein kinase 1-binding protein (TAB)-1a, but not TAB1b, mediates cytokineinduced p38 mitogen-activated protein kinase phosphorylation and cell death in insulin-producing cells. Endocrinology 149, 302-309 (2008).
33. A. Mavropoulos, E. I. Rigopoulou, C. Liaskos, D. P. Bogdanos, L. I. Sakkas, The role of p38 MAPK in the aetiopathogenesis of psoriasis and psoriatic arthritis. Clin. Dev. Immunol. 2013, 1-8 (2013).
34. F. O. Nestle, D. H. Kaplan, J. Barker, Psoriasis. N. Engl. J. Med. 361, 496-509 (2009).
35. T. Cramer, Y. Yamanishi, B. E. Clausen, I. Förster, R. Pawlinski, N. Mackman, V. H. Haase, R. Jaenisch, M. Corr, V. Nizet, G. S. Firestein, H. P. Gerber, N. Ferrara, R. S. Johnson, HIF-1a is essential for myeloid cell-mediated inflammation. Cell 112, 645-657 (2003).
36. B. Fiedler, R. Feil, F. Hofmann, C. Willenbockel, H. Drexler, A. Smolenski, S. M. Lohmann, K. C. Wollert, cGMP-dependent protein kinase type I inhibits TAB1-p38 mitogen-activated protein kinase apoptosis signaling in cardiac myocytes. J. Biol. Chem. 281, 32831-32840 (2006).
37. J. Li, E. J. Miller, J. Ninomiya-Tsuji, R. R. Russell III, L. H. Young, AMP-activated protein kinase activates p38 mitogen-activated protein kinase by increasing recruitment of p38 MAPK to TAB1 in the ischemic heart. Circ. Res. 97, 872-879 (2005).
38. M. Tanno, R. Bassi, D. A. Gorog, A. T. Saurin, J. Jiang, R. J. Heads, J. L. Martin, R. J. Davis, R. A. Flavell, M. S. Marber, Diverse mechanisms of myocardial p38 mitogen-activated protein kinase activation: Evidence for MKK-independent activation by a TAB1-associated mechanism contributing to injury during myocardial ischemia. Circ. Res. 93, 254-261 (2003).
39. Q. Wang, J. Feng, J.Wang, X. Zhang, D. Zhang, T. Zhu, W.Wang, X.Wang, J. Jin, J. Cao, X. Li, H. Peng, Y. Li, B. Shen, J. Zhang, Disruption of TAB1/p38a interaction using a cellpermeable peptide limits myocardial ischemia/reperfusion injury. Mol. Ther. 21, 1668-1677 (2013).
40. F. O. Nestle, P. Di Meglio, J. Z. Qin, B. J. Nickoloff, Skin immune sentinels in health and disease. Nat. Rev. Immunol. 9, 679-691 (2009).
41. B. Ge, X. Xiong, Q. Jing, J. L. Mosley, A. Filose, D. Bian, S. Huang, J. Han, TAB1b (transforming growth factor-b-activated protein kinase 1-binding protein 1b), a novel splicing variant of TAB1 that interacts with p38a but not TAK1. J. Biol. Chem. 278, 2286-2293 (2003).
42. A. A. Ajibade, Q. Wang, J. Cui, J. Zou, X. Xia, M. Wang, Y. Tong, W. Hui, D. Liu, B. Su, H. Y. Wang, R. F. Wang, TAK1 negatively regulates NF-kB and p38 MAP kinase activation in Gr-1+CD11b+ neutrophils. Immunity 36, 43-54 (2012).
43. G. Courties, V. Seiffart, J. Presumey, V. Escriou, D. Scherman, J. Zwerina, G. Ruiz, N. Zietara, J. Jablonska, S. Weiss, A. Hoffmann, C. Jorgensen, F. Apparailly, G. Gross, In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. Blood 116, 3505-3516 (2010).
44. S. Kant, W. Swat, S. Zhang, Z. Y. Zhang, B. G. Neel, R. A. Flavell, R. J. Davis, TNF stimulated MAP kinase activation mediated by a Rho family GTPase signaling pathway. Genes Dev. 25, 2069-2078 (2011).
45. L. Kim, L. Del Rio, B. A. Butcher, T. H. Mogensen, S. R. Paludan, R. A. Flavell, E. Y. Denkers, p38 MAPK auto phosphorylation drives macrophage IL-12 production during intracellular infection. J. Immunol. 174, 4178-4184 (2005).
46. P. C. Cheung, D. G. Campbell, A. R. Nebreda, P. Cohen, Feedback control of the protein kinase TAK1 by SAPK2a/p38a. EMBO J. 22, 5793-5805 (2003).
47. A. Porras, S. Zuluaga, E. Black, A. Valladares, A. M. Alvarez, C. Ambrosino, M. Benito, A. R. Nebreda, P38a mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. Mol. Biol. Cell 15, 922-933 (2004).
48. M. Otsuka, Y. J. Kang, J. Ren, H. Jiang, Y. Wang, M. Omata, J. Han, Distinct effects of p38a deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease. Gastroenterology 138, 1255-1265.e9 (2010).
49. M. Guma, D. Hammaker, K. Topolewski, M. Corr, D. L. Boyle, M. Karin, G. S. Firestein, Anti inflammatory functions of p38 in mouse models of rheumatoid arthritis: Advantages of targeting upstream kinases MKK-3 or MKK-6. Arthritis Rheum. 64, 2887-2895 (2012).
50. X. Guo, R. E. Gerl, J. W. Schrader, Defining the involvement of p38a MAPK in the production of anti- And pro inflammatory cytokines using an SB 203580-resistant form of the kinase. J. Biol. Chem. 278, 22237-22242 (2003).
51. S. Kumar, J. Boehm, J. C. Lee, p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases. Nat. Rev. Drug Discov. 2, 717-726 (2003).
52. D. M. Dambach, Potential adverse effects associated with inhibition of p38a/b MAP kinases. Curr. Top. Med. Chem. 5, 929-939 (2005).
53. S. M. Sa, P. A. Valdez, J.Wu, K. Jung, F. Zhong, L. Hall, I. Kasman, J.Winer, Z. Modrusan, D. M. Danilenko, W. Ouyang, The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J. Immunol. 178, 2229-2240 (2007).
54. M. Toda, D. Y. Leung, S. Molet, M. Boguniewicz, R. Taha, P. Christodoulopoulos, T. Fukuda, J. A. Elias, Q. A. Hamid, Polarized in vivo expression of IL-11 and IL-17 between acute and chronic skin lesions. J. Allergy Clin. Immunol. 111, 875-881 (2003).
55. I. A. Myles, N. M. Fontecilla, P. A. Valdez, P. J. Vithayathil, S. Naik, Y. Belkaid, W. Ouyang, S. K. Datta, Signaling via the IL-20 receptor inhibits cutaneous production of IL-1b and IL- 17A to promote infection with methicillin-resistant Staphylococcus aureus. Nat. Immunol. 14, 804-811 (2013).
56. S. Kumari, M. C. Bonnet, M. H. Ulvmar, K. Wolk, N. Karagianni, E.Witte, C. Uthoff-Hachenberg, J. C. Renauld, G. Kollias, R. Toftgard, R. Sabat, M. Pasparakis, I. Haase, Tumor necrosis factor receptor signaling in keratinocytes triggers interleukin-24-dependent psoriasis-like skin inflammation in mice. Immunity 39, 899-911 (2013).
57. R. Sabat, S. Philipp, C. Höflich, S. Kreutzer, E.Wallace, K. Asadullah, H. D. Volk, W. Sterry, K. Wolk, Immunopa thogenesis of psoriasis. Exp. Dermatol. 16, 779-798 (2007).
58. D. Fang, C. Elly, B. Gao, N. Fang, Y. Altman, C. Joazeiro, T. Hunter, N. Copeland, N. Jenkins, Y. C. Liu, Dysregulation of T lymphocyte function in itchy mice: A role for Itch in TH2 differentiation. Nat. Immunol. 3, 281-287 (2002).
59. V. Heissmeyer, F. Macián, S. H. Im, R. Varma, S. Feske, K. Venuprasad, H. Gu, Y. C. Liu, M. L. Dustin, A. Rao, Calcineurin imposes T cell unresponsiveness through targeted proteolysis of signaling proteins. Nat. Immunol. 5, 255-265 (2004).
60. K. Venuprasad, H. Huang, Y. Harada, C. Elly, M. Subramaniam, T. Spelsberg, J. Su, Y. C. Liu, The E3 ubiquitin ligase Itch regulates expression of transcription factor Foxp3 and airway inflammation by enhancing the function of transcription factor TIEG1. Nat. Immunol. 9, 245-253 (2008).
61. H. S. Jin, Y. Park, C. Elly, Y. C. Liu, Itch expression by Treg cells controls Th2 inflammatory responses. J. Clin. Invest. 123, 4923-4934 (2013).
62. G. N. Maine, H. Li, I. W. Zaidi, V. Basrur, K. S. Elenitoba-Johnson, E. Burstein, A bimolecular affinity purification method under denaturing conditions for rapid isolation of a ubiquitinated protein for mass spectrometry analysis. Nat. Protoc. 5, 1447-1459 (2010).
63. A. I. Nesvizhskii, A. Keller, E. Kolker, R. Aebersold, A statistical model for identifying proteins by tandem mass spectrometry. Anal. Chem. 75, 4646-4658 (2003).